A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesNew and emerging disease modifying therapies for multiple sclerosisCurrent Concepts in Multiple Sclerosis: Autoimmunity Versus OligodendrogliopathyDevelopment of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachTeriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisOral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trialIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineCurrent Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple SclerosisOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisTeriflunomide in Patients with Relapsing-Remitting Forms of Multiple SclerosisRisk Factors for Poor Adherence to Betaferon® Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated SyndromeInfection risk in patients on multiple sclerosis therapeutics.Recent developments in multiple sclerosis therapeuticsThe Diagnosis and Treatment of Optic NeuritisMeasuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?Promising treatments of tomorrow for multiple sclerosis.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisEffectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Participants.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.New oral disease-modifying therapies for multiple sclerosis.Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsMultiple sclerosis: overview of disease-modifying agentsTeriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.New approaches in the management of multiple sclerosis.Escalating immunotherapy of multiple sclerosis.A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).Therapeutic strategies in childhood multiple sclerosisCD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MSCompared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.Kynurenine pathway metabolites in humans: disease and healthy States.Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.Oral disease-modifying therapies for multiple sclerosis.Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.Risk acceptance in multiple sclerosis patients on natalizumab treatment.
P2860
Q22241472-BB346C11-56DA-4A08-B8A8-DEC167E1410EQ22242305-0492EEE5-40E7-4C27-A687-2FB9587091AFQ22252578-2F118D88-788C-43EA-BD4C-D3DCED4DD9A8Q22305854-26206E71-AC6A-4560-8DFC-0393AB6C1749Q24186016-1E6D2C38-F31E-4D05-BF9D-08F1345E60D9Q24198146-2D1AB9FC-78FC-4BA2-8E01-E37815397E6CQ24202177-16E72D23-5C21-4771-9B71-9EB02A24ABC5Q24564715-1D84A933-FAC9-4988-AD9B-806958F7FAD3Q24597369-10686066-D3D9-4D49-B977-599BA394321FQ26740330-6915D090-FBC4-4E31-8D73-C840D83D5E85Q26822611-7A2CB77B-86F0-468F-9271-88E2A4A3A402Q26999417-DB569614-B050-4BC2-9009-C6F66A2154E9Q27000269-A78C1A7B-7E91-443F-81F8-F0B7CE413D9DQ28070118-F11708D1-AC63-44D3-A558-E558BCF05AF0Q28554434-AC937A78-FA06-403A-8611-9225137CBF6FQ30908652-FFBF4727-810F-4222-A95B-9944BE20914BQ30962193-AC2C420B-CD03-47AD-9F3A-D8ED245FE8CFQ30995944-35D13AEE-FB7A-42A1-9470-CDB260A8E102Q33610149-71081EF6-0E6D-4E6F-A261-A7544878B611Q33670947-6FA9DE9A-E24D-44C6-8AD2-8226F88BD6F7Q33802186-09616FEC-76AA-4CF5-99E0-B3D6357C1C72Q33834110-06171DE7-9DA9-442D-9846-C8A238B801B2Q34066654-FD5F6C93-4E85-4489-BEEF-14BDEA20AE24Q34076398-F6DD337A-0A59-460C-BA6F-442190D4D6CAQ34100842-DF0B5AAB-745E-4845-9C49-1C36F5B69570Q34133316-52CE2CA4-F346-4758-929D-38B78F66559DQ34342662-4B2C63F2-DF6F-4199-A40D-2209D791B66DQ34389332-0B440ADB-C3B1-4ADF-A6B2-01B1AA7A212AQ34389528-4E166BA4-1659-44BF-8DC9-AA4055FA072DQ34409100-552EF450-8BC5-4BB7-A075-EB2BD56FEA07Q34409297-9B80FAD3-D1AF-46D7-92F6-15D80D928687Q34409308-8B54DCD3-D080-4F1A-828C-987F1DF098C1Q34409508-BF29B66C-5635-4E6A-8220-7CC2C22081F6Q34556462-A053F0DA-4783-45AD-92BC-6F0654062107Q34630494-06E9BA7A-6AB5-4434-A405-6CBBA157E3A0Q34633683-FA8A6077-CA45-4708-8C9B-81C53E3759B7Q34714866-4DB3A38F-2281-4014-B6BD-BB71811DB0A7Q34996562-E88BDD46-FC6C-4487-92A4-10AF3666BC39Q35047952-D47B05C3-0C7B-4DD5-B9A2-5C379AF0C6B8Q35067882-007406DB-0A46-4481-9572-452A32952EF6
P2860
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A Phase II study of the safety ...... tiple sclerosis with relapses.
@en
A Phase II study of the safety ...... tiple sclerosis with relapses.
@nl
type
label
A Phase II study of the safety ...... tiple sclerosis with relapses.
@en
A Phase II study of the safety ...... tiple sclerosis with relapses.
@nl
prefLabel
A Phase II study of the safety ...... tiple sclerosis with relapses.
@en
A Phase II study of the safety ...... tiple sclerosis with relapses.
@nl
P2093
P1433
P1476
A Phase II study of the safety ...... tiple sclerosis with relapses.
@en
P2093
C Confavreux
G P A Rice
J A Stewart
M S Freedman
P W O'Connor
Teriflunomide Multiple Sclerosis Trial Group
P304
P356
10.1212/01.WNL.0000203121.04509.31
P407
P577
2006-03-01T00:00:00Z